Audit of surgery and chemotherapy for abdominal cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the outcomes of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis from colorectal and ovarian cancers. The study focuses on the effectiveness of this treatment approach in improving patient survival and quality of life. It involves the removal of visible metastatic disease followed by chemotherapy administered at elevated temperatures to target remaining microscopic cancer cells. The study aims to gather data on the procedure's safety and efficacy in a selected patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 to 70 years
2. ASA Class I to III
3. Colorectal and gynecological oncology cases posted for CRS with HIPC.

Exclusion Criteria:

1. Age less than 18 and more than 70 years
2. ASA Class IV and above

Where it's running

• Tata Memorial Hospital
  Mumbai, Maharashtra, India Recruiting

Study contacts

• Principal investigator: Sohan L solanki — Tata Memorial Centre
• Study coordinator: Sohan L Solanki, MD
• Email: me_sohans@yahoo.co.in
• Phone: +919869253201

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• ctDNA-guided precision care for lung, GIST, colorectal, biliary, and ovarian cancers

  This trial tests a blood test that looks for tumor DNA in patients with several cancers to help guide personalized treatment decisions.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07673861

• XYA02 in advanced solid tumors

  This trial tests XYA02 in adults with MUC1-expressing advanced or relapsed solid tumors to see if it is safe, tolerable, and can shrink tumors.

  Recruiting at 2 sites Phase 1/2 XYone Therapeutics, Inc · Sydney, New South Wales and 4 other locations · NCT07670312

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.